International Conference on Alzheimer's and Parkinson's Diseases 2021 (Virtual Meeting)

Barcelona, Spain

09 – 14 March 2021


Back to the Top

Scientists discussed anti-Aβ therapeutic antibodies, confirming their ability to remove brain amyloid and working to boost their brain exposure. They continued their postmortem of BACE inhibitors in hopes of reviving these drugs at lower doses. Efforts at targeting tau are shifting toward tau’s microtubule-binding section, and α-synuclein trials are grappling with rates of disease progression. Emerging neurophysiology-based treatment approached presented promising early stage data, and clinicians shared experiences dealing with a year of COVID disrupting their trials and worsening their patients across neurologic care. Plus: cool news on astrocytes, tau blood tests, better mouse models and more. Check it all out here.

Astroglial Markers Poised for Stardom?

A new PET tracer. Plasma glial fibrillary acidic protein. Two new, promising surrogates for astrogliosis are filling in the Alzheimer’s biomarker toolbox. Both reflect Aβ amyloid better than they do tau tangles.